Allergan recalled its BIOCELL textured breast implants worldwide in 2019 after they were linked to BIA-ALCL — a rare lymphoma. Lawsuits allege women were never adequately warned of the cancer risk.
Allergan's BIOCELL textured breast implants were linked to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) — a rare but serious cancer of the immune system that develops in the tissue surrounding the implant.
In July 2019, the FDA requested a worldwide recall of BIOCELL textured implants after data showed they accounted for the overwhelming majority of BIA-ALCL cases. Lawsuits allege the manufacturer knew of lymphoma risk signals for years but marketed the implants without adequate warnings.
Federal claims are consolidated in a multidistrict litigation in the District of New Jersey (MDL 2921). Claims cover diagnosed BIA-ALCL, explant (removal) surgeries, and medical monitoring — with bellwether proceedings underway.
MDL 2921 in the District of New Jersey is active, with bellwether proceedings scheduled. Claims span diagnosed BIA-ALCL, explant surgeries, and medical-monitoring theories.
Qualification criteria change as litigation develops. The only way to know whether your experience may fit the current criteria is a review.
The Allergan Breast Implant campaign is pre-selected below. Tell us what happened — a specialist will review whether your information may fit the current criteria.
You are reviewing: Allergan Breast Implant Claims. Complete the form — a case specialist may follow up if your information appears to fit.
Attorney advertising. The Torts Attorney provides legal marketing and case-acquisition services and is not a law firm. Submitting this form does not create an attorney-client relationship and does not guarantee review, acceptance, or any outcome. Prior results do not guarantee similar outcomes.